Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
GlaxoSmithKline NZ Limited,Mepolizumab,widening of access (severe eosinophilic asthma 300 cells/ul),Mepolizumab (Nucala),Community and Hospital,Respiratory System and Allergies
